Proposal to widen access to bortezomib for multiple myeloma and amyloidosis

PHARMAC

22 October 2019 - PHARMAC is seeking feedback on the proposal to change the Special Authority criteria for bortezomib.

Following PHARMAC’s 2018/19 Invitation to Tender, PHARMAC is proposing to widen funded access to bortezomib by amending the Special Authority criteria that apply to bortezomib. This proposal would allow bortezomib to be used without further restriction for the treatment of multiple myeloma and amyloid light-chain amyloidosis.

PHARMAC has not yet made a decision on which brand of bortezomib will be funded as a result of the tender. The widening access proposal is dependent on the outcome of the tender, which means that the timing of the access changes, and which brand of bortezomib would be funded at the time, is still to be determined.

Read PHARMAC Consultation

Michael Wonder

Posted by:

Michael Wonder